Guggenheim Downgrades Allergen (AGN) to Neutral on Takeover

Ackman Will Withdraw Request for Special Allergan (AGN) Meeting - CNBC

Pershing Squares Bill Ackman says he's withdrawing his request for a special Allergan (NYSE: AGN) meeting, according to CNBC.

Wells Fargo Downgrades Allergen (AGN) to Market Perform

Wells Fargo downgraded Allergen (NYSE: AGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

SunTrust Downgrades Allergen (AGN) to Neutral

SunTrust Robinson Humphrey downgraded Allergen (NYSE: AGN) from Buy to Neutral.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

William Blair Downgrades Allergen (AGN) to Market Perform

William Blair downgraded Allergen (NYSE: AGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

Actavis (ACT) Agrees to Acquire Allergan (AGN) for ~$219/Share

(Updated - November 17, 2014 9:16 AM EST)

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than... More